A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes

References

• American Diabetes Association. 6 glycemic targets: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S55–s64. Epub 2017/12/10.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and American college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(Suppl 1):1–87. Epub 2015/04/15.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation Guideline Development Group. Guideline for management of postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103:256–268. Epub 2013/03/14.
   PubMed Web of Science ®Google Scholar
• Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–3087. Epub 2013/09/03.
   PubMed Web of Science ®Google Scholar
• DiMarchi RD, Chance RE, Long HB, et al. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Res. 1994;41(Suppl 2):93–96. Epub 1994/01/01.
   PubMedGoogle Scholar
• Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396–402. Epub 1994/03/01.
   PubMed Web of Science ®Google Scholar
• Heinemann L, Heise T, Jorgensen LN, et al. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med. 1993;10:535–539. Epub 1993/07/01.
   PubMed Web of Science ®Google Scholar
• Owens D, Vora J. Insulin aspart: a review. Expert Opin Drug Metab Toxicol. 2006;2:793–804. Epub 2006/10/04.
   PubMed Web of Science ®Google Scholar
• Barlocco D. Insulin glulisine. Aventis Pharma. Curr Opin Invest Drugs. 2003;4:1240–1244. Epub 2003/12/03.
   PubMedGoogle Scholar
• Helms KL, Kelley KW. Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application. Ann Pharmacother. 2009;43:658–668. Epub 2009/04/02.
   PubMed Web of Science ®Google Scholar
• Basu A, Pieber TR, Hansen AK, et al. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. Diabetes Obes Metab. 2018;20:1615–1622. Epub 2018/03/02.
   PubMed Web of Science ®Google Scholar
• Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes. 1999;48:99–105. Epub 1999/01/19.
   PubMed Web of Science ®Google Scholar
• Pandyarajan V, Weiss MA. Design of non-standard insulin analogs for the treatment of diabetes mellitus. Curr Diab Rep. 2012;12:697–704. Epub 2012/9/18.
   PubMed Web of Science ®Google Scholar
• Kang S, Creagh FM, Peters JR, et al. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care. 1991;14:571–577. Epub 1991/07/01.
   PubMed Web of Science ®Google Scholar
• Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14:780–788. Epub 2012/2/11.
   PubMed Web of Science ®Google Scholar
• Heise T, Hovelmann U, Brondsted L, et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17:682–688. Epub 2015/04/08.
   PubMed Web of Science ®Google Scholar
• Home PD. Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? Diabetes Obes Metab. 2015;17:1011–1020. Epub 2015/06/05.
   PubMed Web of Science ®Google Scholar
• Heise T, Pieber TR, Danne T, et al. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. 2017;56:551–559. Epub 2017/2/17.
   PubMed Web of Science ®Google Scholar
• Buse JB, Carlson AL, Komatsu M, et al. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial. Diabetes Obes Metab. 2018;20:2885–2893. Epub 2018/9/28.
   PubMedGoogle Scholar
• Russell-Jones D, Bode BW, De Block C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (Onset 1). Diabetes Care. 2017;40:943–950. Epub 2017/3/31.
   PubMed Web of Science ®Google Scholar
• Bowering K, Case C, Harvey J, et al. Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2 trial. Diabetes Care. 2017;40:951–957. Epub 2017/5/10.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Tripathy D, Vidrio Velazquez M, et al. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomized, 18-week, open-label, phase 3 trial (Onset 3). Diabetes Obes Metab. 2017;19:1389–1396. Epub 2017/3/28.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Heller SR, Buchs S, et al. Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting. Diabetes Obes Metab. 2017;19:1773–1780. Epub 2017/6/03.
   PubMed Web of Science ®Google Scholar
• Cengiz E. Undeniable need for ultrafast-acting insulin: the pediatric perspective. J Diabetes Sci Technol. 2012;6:797–801. Epub 2012/8/28.
   PubMedGoogle Scholar
• Ligthelm RJ, Kaiser M, Vora J, et al. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc. 2012;60:1564–1570. Epub 2012/8/14.
   PubMed Web of Science ®Google Scholar
• Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–3417. Epub 2013/7/24.
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535–1540. Epub 2004/6/29.
   PubMed Web of Science ®Google Scholar
• Rubino A, McQuay LJ, Gough SC, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24:1412–1418. Epub 2007/11/29.
   PubMed Web of Science ®Google Scholar
• Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol. 2012;166:159–170. Epub 2011/9/21.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Raz I. Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom? Diabetes Care. 2013;36(Suppl 2):S212–8. Epub 2013/8/02.
   PubMed Web of Science ®Google Scholar
• Pfeiffer KM, Sandberg A, Nikolajsen A, et al. Postprandial glucose and healthcare resource use: a cross-sectional survey of adults with diabetes treated with basal-bolus insulin. J Med Econ. 2018;21:66–73. Epub 2017/9/07.
   PubMed Web of Science ®Google Scholar